Medical Devices and Technologies
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities
Our global medical devices and technologies group acts for companies and institutions across the sector and provides advice to ensure that clients are well placed to manage the challenges they face to capitalise on opportunities.
Our team spans disciplines including intellectual property (contentious and non-contentious), regulatory, product liability, mergers and acquisitions, commercial transactions (including licensing and collaborations), and capital markets and finance matters.
Our international network ensures that we have a ready resource of expertise in a wide range of jurisdictions and that we are well positioned to advise on cross-border work. Our lawyers have been advising clients in the sector for many years and have developed a deep understanding of the issues affecting the industry. This ensures that we add value to any matter and there is no learning curve.
For example, our team has been closely following the current proposed changes to the European medical devices regulatory framework. We have also been tracking and advising our clients on regulatory issues in the context of emerging technologies such as device/drug combinations, medical apps and other “connected health” initiatives. In these areas we use our broad and interdisciplinary experience to help our clients navigate what may often be rapidly evolving or uncertain regulatory pathways and manage the risks of new product development.
Our clients in the medical devices sector include Biomet, Samsung, GE Healthcare, Johnson & Johnson, Fresenius, Covidien, St Jude Medical and Novartis.
News & insights
Publications: 19 FEBRUARY 2020
On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement).Read more
News: 07 JANUARY 2020
A&O has marked the end of Q4 2019 with a stellar performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more
Publications: 29 NOVEMBER 2019
As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.Read more
Publications: 04 OCTOBER 2019
A&O has marked the end of Q3 2019 with an outstanding performance in the M&A league tables; the result of advising on a number of complex, high-value transactions in a wide range of sectors and markets, around our global network in 2019.Read more